Sera Prognostics, Inc.
NGM: SERALive Quote
📈 ZcoreAI Score
Our AI model analyzes Sera Prognostics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SERA Z-Score →About Sera Prognostics, Inc.
Healthcare
Medical Devices
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
📊 Fundamental Analysis
Sera Prognostics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -58.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -51.8%, which indicates that capital utilization is currently under pressure.
At a current price of $1.97, SERA currently sits at the 22nd percentile of its 52-week range (Range: $1.37 - $4.09).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$77.11M
Trailing P/E
--
Forward P/E
-2.94
Beta (5Y)
1.06
52W High
$4.09
52W Low
$1.37
Avg Volume
60K
Day High
Day Low